Acquisition momentum Cantel Medical is now part of STERIS, with a history of strategic acquisitions (Hu-Friedy, Omnia) and a recent $4.6B integration. This signals a strong channel for cross-sell opportunities in infection prevention and endoscope reprocessing solutions across extended product portfolios.

Infection prevention focus As a leading provider of infection prevention products and services, Cantel (STERIS) presents ongoing demand for advanced sterilization, reprocessing software, and compliance services—areas ripe for upsell with hospitals and outpatient facilities investing in safer patient outcomes.

Endoscope ecosystem Cantel’s involvement in endoscope reprocessing software development and integration partners suggests opportunities to propose upgraded reprocessing workflows, digital traceability, and training services to customers expanding scope of practice and regulatory compliance needs.

Dental and surgical expansions Acquisitions like Hu-Friedy indicate a broadened dental and surgical portfolio. Sales outreach can target dental clinics and perioperative environments with combined infection control products, consumables, and service contracts.

Mid-market growth channel With a revenue range in the tens of millions and a sizable employee base, Cantel/STERIS operates in a mid-market segment that benefits from scalable service offerings, bundled procurement programs, and repeat-buys for consumables, training, and software licenses.